These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 26306734)

  • 21. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
    Haricharan S; Punturi N; Singh P; Holloway KR; Anurag M; Schmelz J; Schmidt C; Lei JT; Suman V; Hunt K; Olson JA; Hoog J; Li S; Huang S; Edwards DP; Kavuri SM; Bainbridge MN; Ma CX; Ellis MJ
    Cancer Discov; 2017 Oct; 7(10):1168-1183. PubMed ID: 28801307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
    Sarosiek T
    Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of CDK4/6 Inhibitors: A Five Years Update.
    Ammazzalorso A; Agamennone M; De Filippis B; Fantacuzzi M
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33803309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Yang C; Li Z; Bhatt T; Dickler M; Giri D; Scaltriti M; Baselga J; Rosen N; Chandarlapaty S
    Oncogene; 2017 Apr; 36(16):2255-2264. PubMed ID: 27748766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Therapeutic Strategies in Breast Cancer.
    Cox K; Alford B; Soliman H
    South Med J; 2017 Oct; 110(10):632-637. PubMed ID: 28973703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
    Pandey K; An HJ; Kim SK; Lee SA; Kim S; Lim SM; Kim GM; Sohn J; Moon YW
    Int J Cancer; 2019 Sep; 145(5):1179-1188. PubMed ID: 30478914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDK4/6 inhibitors in breast cancer - from
    Saleh L; Wilson C; Holen I
    Acta Oncol; 2020 Feb; 59(2):219-232. PubMed ID: 31671026
    [No Abstract]   [Full Text] [Related]  

  • 29. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
    Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
    Knudsen ES; Witkiewicz AK
    Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
    Zhang H; Wang J; Li J; Zhou X; Yin L; Wang Y; Gu Y; Niu X; Yang Y; Ji H; Zhang Q
    Cancer Sci; 2021 Apr; 112(4):1603-1613. PubMed ID: 33453094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
    Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
    Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
    Lynce F; Shajahan-Haq AN; Swain SM
    Pharmacol Ther; 2018 Nov; 191():65-73. PubMed ID: 29933034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
    Owsley J; Jimeno A; Diamond JR
    Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting breast cancer with CDK inhibitors.
    Mayer EL
    Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Therapeutic Effects of Specific CDK4/6-inhibitors in Treating HR-positive, HER2-negative Advanced Breast Cancer.
    Luis M
    Klin Onkol; 2018; 31(4):305-308. PubMed ID: 30541316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.
    Xu XQ; Pan XH; Wang TT; Wang J; Yang B; He QJ; Ding L
    Acta Pharmacol Sin; 2021 Feb; 42(2):171-178. PubMed ID: 32504067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
    Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.
    Fogli S; Del Re M; Curigliano G; van Schaik RH; Lancellotti P; Danesi R
    Cancer Treat Rev; 2019 Mar; 74():21-28. PubMed ID: 30685576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.